Skip to content

Circles

T

Telomir Pharmaceuticals, Inc.

TELO· Nasdaq

T

TELOTelomir Pharmaceuticals, Inc.

TELOTelomir Pharmaceuticals, Inc.·Earnings record

Q2 2023

Source filing unavailable

Previous · Q1 2023 Next · Q3 2023

Q2 2023 · —

Revenue—

Net Income

-$1.55M

no prior Q2 2022 on file

EPS Diluted

-$0.06

no prior Q2 2022 on file

Operating Cash Flowderived-$33,577—

Same quarter

no prior Q2 2022 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Filing lag

Quarterly history

Q1 ’23Q2 ’23Q3 ’23 Q4 ’23 Q1 ’24 Q2 ’24 Q3 ’24 Q4 ’24^d Q1 ’25…

Telomir Pharmaceuticals, Inc. · CIK 1971532 · Engraved from SEC EDGAR

Thaler ResearchEngraved from SEC EDGAR© 2026 Thaler. All rights reserved.Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Platform

Using AI API SDKs CLI

Research

News Listen Earnings Insiders Holders Compare Metrics

Screener Watchlists Pies Notes Your companies

Learn

Thaler

Thaler Agent Promise Provenance Circles Account Terms Privacy